Option chain shows key data for SSC Security Services's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for SSC Security Services.

SSC Security Services (OTC:SECUF) Stock, Option Chain

SSC Security Services

SSC Security Services Corp is a provider of physical and cyber security services to corporate and public sector clients across Canada. The company operates in three segments which include Security, Legacy Operations, and Corporate, and the majority of its revenue is generated from The security segment.

SSC SEC SVCS CORP by SSC Security Services Corp.

SSC Security Services Corp

<p>Over the last 6 sessions, many formerly high-flying stocks are down, massively. PLTR has lost over 31% during this period. SCMI shed almost the same. TSLA is down over 22%.</p>
<p>While many of these tickers may have good long-term reasons to be bullish, knowing when to take profits, when to protect the downside, and when to flip bearish is crucial.</p>
<p>There is no technical indicator or chart that is going to give you that information. Option dealers and market makers don't care about your support and resistance levels. They have to delta hedge regardless of whether your levels are breached.&nbsp; And any horizontal levels you pick on your chart will rarely ever depict where and when volatility will increase and the chances for your ticker to go bearish jump.</p>
<p>What if you could know for any ticker you trade when it becomes more vulnerable? What if you could know at what price the option dealers and market makers are going to sell as it falls, not buy? How about knowing when volatility could expand and thus kick your stop losses or take on bigger moves?</p>
<p><strong><u>There is a way to find this exact price.</u></strong></p>
<p>Here at Benzinga, and particularly in the Benzinga Option School, we've built a proprietary indicator that does just this. We call it the BBP level, otherwise known as the Bull/Bear Pivot level.</p>
<p>While I'm not going to give away the keys to the kingdom, I can tell you this proprietary indicator is based upon two key principles (and a lot of quantitative data). First, it's based upon option positioning (all of it for each ticker). Second, it estimates exactly where the option dealer and market maker hedging shifts to where the dealers will have to sell if the market goes down, not buy.</p>
<p>If you buy a dip and the dealers are buying, the chances of your bullish trade working out increase dramatically. But if you buy a dip and the dealers are forced to sell, they are trading against you, and you're fighting against a much larger force that will severely impact your trade.</p>
<p>This is exactly what the BBP level provides our <strong>Benzinga Option School</strong> members, and it can give you a massive edge on knowing when to buy that dip, or to sell. When to hedge or keep your bullish exposure. When to reduce leverage or buy downside protection.</p>
<p>Let me give a few examples below of the BBP level in action:</p>
<h2 class="wp-block-heading">TSLA &amp; the BBP Level</h2>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="612" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145128/tsla-gamma-1024x612.png" alt="" class="wp-image-804428" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145128/tsla-gamma-1024x612.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145128/tsla-gamma-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145128/tsla-gamma-768x459.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145128/tsla-gamma.png 1289w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p>The chart above shows many of our proprietary quantitative levels for Tesla option positioning, particularly examining a primary variable for the open interest.</p>
<p>You'll see pink bars on the left (puts) and blue bars on the right (calls).</p>
<p>On the top left, you'll see an orange flag which says "Pivot" on it. That is our BBP level, our Bull/Bear Pivot. Here, that ‘pivot' is lined up at $400.</p>
<p>The basic rules of thumb when using and trading with this is as follows:</p>
<ol>
<li>When the stock trades below the BBP level, we take profits on our bullish positions + do not add any new bullish positions</li>
<li>If we get deeper into the pink territory (all depends upon the structure of the pink bars), we then consider hedging any long stock positions we want to keep.</li>
<li>If certain ‘changes' happen in our structure or levels, then we'll look for outright bearish positions.</li>
</ol>
<p>If you look at the following chart below for Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), you can see that once we had our impulsive break and close below $400, it's been (for the most part) a one-way train, losing over 29% since and only weak/corrective bounces.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145156/TSLA_2025-02-27_14-26-26-1024x502.png" alt="" class="wp-image-804430" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145156/TSLA_2025-02-27_14-26-26-1024x502.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145156/TSLA_2025-02-27_14-26-26-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145156/TSLA_2025-02-27_14-26-26-768x377.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145156/TSLA_2025-02-27_14-26-26-1536x753.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145156/TSLA_2025-02-27_14-26-26.png 1835w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p class="has-text-align-center"><em>TSLA 1hr chart</em></p>
<p>Now I'd like you to think about what it would be like to have a level, that if you break below, you either a) trim your bullish positions, b) maybe sell some calls to lower your cost basis, c) start to hedge and protect your downside, or d) shift to outright bearish mode and make money as the stock goes down?</p>
<p>What would that do for your trading to have these levels every day?</p>
<p>How much money would it save you holding onto losing positions?</p>
<p>What would it do for your confidence to ‘know' when to start shifting from bullish to bearish with clarity?</p>
<p>By the way, let me let you in on a few other BBP levels:</p>
<ul>
<li>On February 19, our BBP level for Palantir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) was $115, and it closed at $112 on that day. Since then, it's lost 24%.</li>
<li>On February 25, Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) had its BBP level at $53. The next day, it fell below our BBP level and has dropped 15% since.</li>
<li>NVDA had its BBP level at $130, as I'm writing this, which I  warned our Benzinga Option School members about ahead of time, saying:</li>
</ul>
<p>"<em>If NVDA can recapture 140, this means calls are completely in control, so should find more supportive flows above there. Meanwhile <strong>losing 130 would bring puts more into control</strong>, and thus <u>a more vulnerable position for NVDA</u>."</em></p>
<p>I told our members <em>before</em> the market opened that if NVDA fell below the 130 level (the BBP level), it would be vulnerable to losses as dealers would start selling as it fell.</p>
<p>NVDA closed today at $10 lower and $120.31.&nbsp;</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145217/NVDA_2025-02-27_14-41-59-1024x502.png" alt="" class="wp-image-804431" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145217/NVDA_2025-02-27_14-41-59-1024x502.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145217/NVDA_2025-02-27_14-41-59-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145217/NVDA_2025-02-27_14-41-59-768x377.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145217/NVDA_2025-02-27_14-41-59-1536x753.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145217/NVDA_2025-02-27_14-41-59.png 1835w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p class="has-text-align-center"><em>NVDA 5min chart</em></p>
<p>Our members were prepared <strong><em>ahead</em> of time</strong> to reduce bullish positions and start looking for bearish plays.</p>
<p>Had you known about this today, you likely would have saved yourself a ton of money. Now imagine that but having the knowledge and level every day you trade. What would that do for your trading? How many big losses would be smaller? How many times would you be able to profit from a shift in bearish positioning?</p>
<p>That is the power of the BBP level.</p>
<p>If you'd like to learn more about the BBP level, or see me use trading live, you can become a member of the <strong><a href="https://www.benzinga.com/premium/ideas/benzinga-options-school-webinar/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD0301&amp;utm_campaign=optionsschool">Benzinga Option School.</a></strong></p>
<p>I look forward to working with you and teaching you how to use this BBP level for your trading.</p>
<p>Image via MidJourney AI</p>


Opinion

Trading Ideas

PLTR

SMCI

TSLA

How I Saw This Tech Crash Coming a Mile Away – And You Could Have Too

WIIM

CARS

Cars.Com shares are trading higher, reversing after falling Thursday on worse-than-expected Q4 financial results.

<p>In the latest quarter, 11 analysts provided ratings for Aflac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Aflac, revealing an average target of $103.64, a high estimate of $118.00, and a low estimate of $94.00. Surpassing the previous average price target of $103.00, the current average has increased by 0.62%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772856_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Aflac. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$105.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$102.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$104.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$95.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$118.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Jack Matten</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$111.00</td>
<td>-</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$104.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$107.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$98.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Thomas Gallagher</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$102.00</td>
<td>$104.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Aflac. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Aflac compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Aflac's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Aflac's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AFL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Aflac analyst ratings.</strong></a></p>
<h2>Discovering Aflac: A Closer Look</h2>
<p>Aflac Inc offers supplemental health insurance and life insurance in the United States and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accident, dental and vision, disability, and long-term-care insurance. It markets its products through independent distributors, selling the majority of its policies directly to consumers at their places of work, and also reaches out to its customers outside of their worksite through digital mediums. The company has two reportable business segments; Aflac Japan which generates the majority of the revenue, and Aflac U.S.</p>
<h3>Aflac: A Financial Overview</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Aflac's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>44.53%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Aflac's net margin excels beyond industry benchmarks, reaching <strong>34.59%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>7.47%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.55%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Aflac's debt-to-equity ratio is below the industry average at <strong>0.29</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

11 Analysts Have This To Say About Aflac

<p>In the latest quarter, 8 analysts provided ratings for Lincoln National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNC#NYSE">LNC</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $37.88, a high estimate of $44.00, and a low estimate of $28.00. This upward trend is evident, with the current average reflecting a 6.7% increase from the previous average price target of $35.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772849_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Lincoln National among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$42.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Thomas Gallagher</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$44.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$36.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$39.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$40.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$36.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lincoln National. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lincoln National compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Lincoln National's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>To gain a panoramic view of Lincoln National's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LNC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Lincoln National analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Lincoln National</h2>
<p>Lincoln National Corp operates multiple insurance and retirement businesses. The company's operating segment includes Annuities; Retirement Plan Services; Life Insurance and Group Protection. Its products include fixed and indexed annuities, variable annuities, universal life insurance (UL), variable universal life insurance (VUL), linked-benefit UL and VUL, indexed universal life insurance (IUL), term life insurance, employer-sponsored retirement plans and services, and group life, disability and dental.</p>
<h3>Understanding the Numbers: Lincoln National's Finances</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Lincoln National's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>605.13%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Lincoln National's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>32.91%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Lincoln National's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>21.86%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Lincoln National's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.42%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Lincoln National's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.87</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Lincoln National Through 8 Analysts

<p>Deep-pocketed investors have adopted a bullish approach towards Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LUNR usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 18 extraordinary options activities for Intuitive Machines. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 44% leaning bullish and 38% bearish. Among these notable options, 5 are puts, totaling $330,540, and 13 are calls, amounting to $4,304,059.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $10.5 to $19.0 for Intuitive Machines over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Intuitive Machines's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Intuitive Machines's substantial trades, within a strike price spectrum from $10.5 to $19.0 over the preceding 30 days.</p>
<h3>Intuitive Machines 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772847_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>LUNR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.55</td>
<td>$3.5</td>
<td>$3.55</td>
<td>$12.00</td>
<td>$1.8M</td>
<td>2.0K</td>
<td>7.9K</td>
</tr>
<tr>
<td>LUNR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.5</td>
<td>$3.45</td>
<td>$3.45</td>
<td>$12.00</td>
<td>$764.3K</td>
<td>2.0K</td>
<td>13.5K</td>
</tr>
<tr>
<td>LUNR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.6</td>
<td>$3.55</td>
<td>$3.6</td>
<td>$12.00</td>
<td>$679.5K</td>
<td>2.0K</td>
<td>15.6K</td>
</tr>
<tr>
<td>LUNR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.45</td>
<td>$3.0</td>
<td>$3.35</td>
<td>$12.00</td>
<td>$477.8K</td>
<td>2.0K</td>
<td>61</td>
</tr>
<tr>
<td>LUNR</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$5.1</td>
<td>$4.9</td>
<td>$5.0</td>
<td>$19.00</td>
<td>$100.0K</td>
<td>1.1K</td>
<td>205</td>
</tr>
</tbody>
</table>
</p>
<h3>About Intuitive Machines</h3>
<p>Intuitive Machines Inc is a space exploration, infrastructure, and services company. It is a diversified space company focused on space exploration. It supplies space products and services to support sustained robotic and human exploration to the Moon, Mars, and beyond. Its products and services are offered through its four business units: Lunar Access Services, Orbital Services, Lunar Data Services, and Space Products and Infrastructure.</p>
<h3>Current Position of Intuitive Machines</h3>
<ul>
<li>Trading volume stands at 13,228,001, with LUNR's price up by 2.4%, positioned at $14.74.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 20 days.</li>
</ul>
<h3>What The Experts Say On Intuitive Machines</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $16.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from B of A Securities downgraded its action to Underperform with a price target of $16. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Intuitive Machines options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Markets

LUNR

Decoding Intuitive Machines's Options Activity: What's the Big Picture?

<p>Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) has outperformed the market over the past 5 years by 17.19% on an annualized basis producing an average annual return of 31.55%. Currently, Fluor has a market capitalization of $6.43 billion. </p>
<p><strong>Buying $1000 In FLR:</strong> If an investor had bought $1000 of FLR stock 5 years ago, it would be worth <strong>$3,794.82</strong> today based on a price of $38.10 for FLR at the time of writing.</p>
<h3>Fluor's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772846_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


News

Here's How Much $1000 Invested In Fluor 5 Years Ago Would Be Worth Today

<p>Ratings for Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $16.38, a high estimate of $32.00, and a low estimate of $6.00. Highlighting a 10.88% decrease, the current average has fallen from the previous average price target of $18.38. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772842_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Iovance Biotherapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Ulz</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$7.50</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$32.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.50</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Iovance Biotherapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Iovance Biotherapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Iovance Biotherapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Iovance Biotherapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IOVA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Iovance Biotherapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Delving into Iovance Biotherapeutics's Background</h2>
<p>Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.</p>
<h3>Financial Insights: Iovance Biotherapeutics</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Iovance Biotherapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>12384.86%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-142.67%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Iovance Biotherapeutics's ROE excels beyond industry benchmarks, reaching <strong>-10.84%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Iovance Biotherapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-8.54%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Iovance Biotherapeutics's debt-to-equity ratio is below the industry average at <strong>0.1</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


IOVA

Forecasting The Future: 4 Analyst Projections For Iovance Biotherapeutics

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Axon Enterprise</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AXON, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 27 uncommon options trades for Axon Enterprise.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 29% bullish and 51%, bearish.</p>
<p>Out of all of the special options we uncovered, 11 are puts, for a total amount of $805,664, and 16 are calls, for a total amount of $1,363,222.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $195.0 to $720.0 for Axon Enterprise during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Axon Enterprise's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Axon Enterprise's whale activity within a strike price range from $195.0 to $720.0 in the last 30 days. </p>
<h3>Axon Enterprise Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772841_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$62.4</td>
<td>$58.5</td>
<td>$61.3</td>
<td>$470.00</td>
<td>$619.1K</td>
<td align="right">175</td>
<td align="right">0</td>
</tr>
<tr>
<td>AXON</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$126.3</td>
<td>$122.8</td>
<td>$125.0</td>
<td>$650.00</td>
<td>$275.0K</td>
<td align="right">169</td>
<td align="right">23</td>
</tr>
<tr>
<td>AXON</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$41.4</td>
<td>$40.0</td>
<td>$40.0</td>
<td>$500.00</td>
<td>$200.0K</td>
<td align="right">100</td>
<td align="right">52</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$19.9</td>
<td>$18.0</td>
<td>$18.0</td>
<td>$650.00</td>
<td>$162.0K</td>
<td align="right">433</td>
<td align="right">90</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$187.0</td>
<td>$184.5</td>
<td>$184.5</td>
<td>$400.00</td>
<td>$92.2K</td>
<td align="right">4</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Axon Enterprise</h3>
<p>Axon Enterprise Inc develops, manufactures, and sells conducted energy devices and cloud-based digital evidence management software designed for use by law enforcement, corrections, military forces, private security personnel, and private individuals for personal defense. The company operates in two segments: Taser and software &amp; sensors. Taser develops and sells CEDs used for protecting users and virtual reality training. Software and sensors manufacture fully integrated hardware and cloud-based software solutions such as body cameras, automated license plate reading, and digital evidence management systems. Axon delivers its products worldwide and derives the majority of its revenue from the software &amp; sensors segment and geographically from the United States.</p>
<h3>Axon Enterprise's Current Market Status</h3>
<ul>
<li>With a trading volume of 448,737, the price of AXON is down by -0.08%, reaching $525.03.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 66 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Axon Enterprise</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $680.2.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $600.<br />
&#x2A; An analyst from Barclays persists with their Overweight rating on Axon Enterprise, maintaining a target price of $726.<br />
&#x2A; Reflecting concerns, an analyst from Craig-Hallum lowers its rating to Hold with a new price target of $625.<br />
&#x2A; Maintaining their stance, an analyst from JMP Securities continues to hold a Market Outperform rating for Axon Enterprise, targeting a price of $725.<br />
&#x2A; An analyst from Citizens Capital Markets has revised its rating downward to Market Outperform, adjusting the price target to $725. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Axon Enterprise, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


AXON

Looking At Axon Enterprise's Recent Unusual Options Activity

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Oklo</strong>.</p>
<p>Looking at options history for Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) we detected 35 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 48% of the investors opened trades with bullish expectations and 42% with bearish.</p>
<p>From the overall spotted trades, 20 are puts, for a total amount of $852,722 and 15, calls, for a total amount of $675,968.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $20.0 to $47.0 for Oklo over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Oklo's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Oklo's substantial trades, within a strike price spectrum from $20.0 to $47.0 over the preceding 30 days.</p>
<h3>Oklo Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772836_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>OKLO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.9</td>
<td>$5.65</td>
<td>$5.73</td>
<td>$22.50</td>
<td>$257.8K</td>
<td>979</td>
<td>1.0K</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/07/25</td>
<td>$2.26</td>
<td>$2.14</td>
<td>$2.14</td>
<td>$36.00</td>
<td>$85.6K</td>
<td>180</td>
<td>892</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.3</td>
<td>$5.9</td>
<td>$6.3</td>
<td>$30.00</td>
<td>$62.3K</td>
<td>3.1K</td>
<td>118</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$11.9</td>
<td>$11.2</td>
<td>$11.8</td>
<td>$34.00</td>
<td>$59.0K</td>
<td>15</td>
<td>62</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$12.15</td>
<td>$11.5</td>
<td>$11.72</td>
<td>$33.00</td>
<td>$58.6K</td>
<td>29</td>
<td>50</td>
</tr>
</tbody>
</table>
</p>
<h3>About Oklo</h3>
<p>Oklo Inc is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale. It is pursuing two complementary tracks to address this demand: providing reliable, commercial-scale energy to customers; and selling used nuclear fuel recycling services to the U.S. market. The Company plans to commercialize its liquid metal fast reactor technology with the Aurora powerhouse product line. The first commercial Aurora powerhouse is designed to produce up to 15 megawatts of electricity (MWe) on both recycled nuclear fuel and fresh fuel.</p>
<p>In light of the recent options history for Oklo, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Oklo</h3>
<ul>
<li>With a volume of 11,182,131, the price of OKLO is up 2.07% at $33.06. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 11 days.</li>
</ul>
<h3>What The Experts Say On Oklo</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $58.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from B. Riley Securities persists with their Buy rating on Oklo, maintaining a target price of $58. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Oklo with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


OKLO

Oklo's Options: A Look at What the Big Money is Thinking

<p>In the latest quarter, 8 analysts provided ratings for Vertex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERX#NASDAQ">VERX</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $51.75, a high estimate of $62.00, and a low estimate of $31.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 10.11%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772832_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The perception of Vertex by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>William Jellison</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$55.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$31.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>William Jellison</td>
<td>DA Davidson</td>
<td>Announces</td>
<td>Buy</td>
<td>$62.00</td>
<td>-</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$58.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$54.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$61.00</td>
<td>$61.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Vertex. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Vertex compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Capture valuable insights into Vertex's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VERX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Vertex analyst ratings.</strong></a></p>
<h2>Delving into Vertex's Background</h2>
<p>Vertex Inc is a provider of tax technology and services. Its software, content, and services help customers stay in compliance with indirect taxes that occur in taxing jurisdictions all over the world. Vertex provides cloud-based and on-premise solutions to specific industries for every line of tax, including income, sales, consumer use, value-added, and payroll. The company offers solutions such as tax determination, Tax Data Management, document management, and compliance and reporting among others. The company derives revenue from software subscriptions.</p>
<h3>Financial Insights: Vertex</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Vertex's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>17.52%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Vertex's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>4.24%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Vertex's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>2.93%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.65%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.36</strong>, caution is advised due to increased financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


VERX

What Analysts Are Saying About Vertex Stock

<p>Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $192.56, a high estimate of $200.00, and a low estimate of $180.00. This current average reflects an increase of 13.44% from the previous average price target of $169.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772825_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A comprehensive examination of how financial experts perceive Natera is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$195.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$188.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Eve Burstein</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Julia Qin</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Natera. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Natera compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Natera's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Natera's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NTRA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Natera analyst ratings.</strong></a></p>
<h2>Delving into Natera's Background</h2>
<p>Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.</p>
<h3>Natera: A Financial Overview</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Natera showcased positive performance, achieving a revenue growth rate of <strong>63.9%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Natera's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-7.18%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Natera's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-3.68%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Natera's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-2.03%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Natera's debt-to-equity ratio is below the industry average at <strong>0.54</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NTRA

Deep Dive Into Natera Stock: Analyst Perspectives (9 Ratings)

<p>In the latest quarter, 13 analysts provided ratings for Equitable Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQH#NYSE">EQH</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">10</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $61.31, a high estimate of $72.00, and a low estimate of $53.00. Witnessing a positive shift, the current average has risen by 9.0% from the previous average price target of $56.25.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772814_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Equitable Holdings by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$66.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Jack Matten</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$62.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$61.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$61.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Jack Matten</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Cave Montazeri</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$58.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$53.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$61.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$54.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Equitable Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Equitable Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Equitable Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Equitable Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EQH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Equitable Holdings analyst ratings.</strong></a></p>
<h2>All You Need to Know About Equitable Holdings</h2>
<p>Equitable Holdings Inc is a financial services company in the U.S. The company provides variable annuities, tax-deferred investment and retirement plans, employee benefits, and protection solutions for individuals, families, and small businesses. Its business segments include Individual Retirement, Group Retirement, Asset Management, Protection Solutions, Wealth Management, and Legacy. It generates the majority of its revenue from the Asset Management segment which provides diversified investment management and related solutions globally to a broad range of clients through three main client channels - Institutional, Retail, and Private Wealth.</p>
<h3>Breaking Down Equitable Holdings's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Equitable Holdings showcased positive performance, achieving a revenue growth rate of <strong>66.87%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Equitable Holdings's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>24.11%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Equitable Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>100.58%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Equitable Holdings's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.29%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>76.27</strong>, caution is advised due to increased financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 13 Analyst Projections For Equitable Holdings

AMPH

Amphastar Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 financial results.

LZMH

LZ Technology shares are trading higher following Thursday's IPO.

CDXS

Codexis shares are trading lower after the company reported worse-than-expected Q4 financial results.

<p>As financial markets <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/02/43955914/market-could-enter-a-real-correction-expert-warns">cooled off in February</a>, investor sentiment spiked downwards near a historic low. However, past bearishness has often amplified returns in the future.</p>
<p><strong>What Happened:</strong> The AAII Investor Sentiment Survey found investors particularly <a href="https://www.aaii.com/sentimentsurvey">bearish</a> in the week ending Feb. 26.</p>
<p>Of the investors surveyed, 19.4% had a bullish outlook on the economy, 20% were neutral and 60.6% were bearish. This marks the highest level of bearish sentiment this year, well above the historical average of 31%, and only briefly exceeded in September 2022.</p>
<p>Poor sentiment is likely tied to sticky inflation, possible tariffs from the Trump Administration and a pullback in the artificial intelligence industry.</p>
<p><strong>Why it Matters:</strong> According to LPL Financial, markets frequently <a href="https://www.lpl.com/research/blog/investor-sentiment-hits-extremely-bearish-levels.html">overperform</a> following periods of extreme bearishness.</p>
<p>&#8220;&#8230;historically, when the bull-bear spread has been at comparable levels of more than two standard deviations below the average (which has occurred only 4.1% of the time going back to July 1987), S&amp;P 500 returns have been above average,&#8221; a report from LPL&#8217;s <strong>George Smith</strong> said.</p>
<p>Following &#8220;extremely bearish&#8221; sentiment spreads, the <strong>SPDR S&amp;P 500 ETF Trust</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) has historically returned over 10% within a year, higher than the average return during bullish markets.</p>
<p>LPL Financial also noted the Bank of America Global Fund Manager Survey, which painted a rosier picture of sentiment on Wall Street. Survey respondents are cautiously optimistic, with 82% believing a global recession is unlikely in the next year.</p>
<p>Year-to-date, the S&amp;P 500 is roughly even, following a strong year for the index in 2024. The tech-focused <strong>NASDAQ</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) has fared worse, shedding 1.78% of its value in 2025.</p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/02/44049626/key-inflation-measure-falls-in-january-should-catch-the-feds-attention-expert-says">Key Inflation Measure Falls In January: &#8216;Should Catch The Fed&#8217;s Attention,&#8217; Economist Says</a></strong></li>
</ul>
<p><em>Image created using artificial intelligence via Midjourney.</em></p>


Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

Investor Bearishness Surges, Yet Historical Data Suggests Potential Market Gains Ahead

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Victoria's Secret</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VSCO, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Victoria's Secret.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 70% bullish and 20%, bearish.</p>
<p>Out of all of the special options we uncovered, 5 are puts, for a total amount of $197,472, and 5 are calls, for a total amount of $176,891.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $25.0 and $30.0 for Victoria's Secret, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Victoria's Secret options trades today is 1100.83 with a total volume of 4,589.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Victoria's Secret's big money trades within a strike price range of $25.0 to $30.0 over the last 30 days.</p>
<h3>Victoria's Secret Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740771960_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>VSCO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.8</td>
<td>$4.6</td>
<td>$4.65</td>
<td>$30.00</td>
<td>$46.5K</td>
<td>1.0K</td>
<td>402</td>
</tr>
<tr>
<td>VSCO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.8</td>
<td>$4.6</td>
<td>$4.64</td>
<td>$30.00</td>
<td>$46.5K</td>
<td>1.0K</td>
<td>720</td>
</tr>
<tr>
<td>VSCO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.8</td>
<td>$4.6</td>
<td>$4.65</td>
<td>$30.00</td>
<td>$46.0K</td>
<td>1.0K</td>
<td>820</td>
</tr>
<tr>
<td>VSCO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.2</td>
<td>$2.1</td>
<td>$2.2</td>
<td>$27.00</td>
<td>$44.0K</td>
<td>1.6K</td>
<td>1.0K</td>
</tr>
<tr>
<td>VSCO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$3.8</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$25.00</td>
<td>$37.0K</td>
<td>2.6K</td>
<td>100</td>
</tr>
</tbody>
</table>
</p>
<h3>About Victoria's Secret</h3>
<p>Victoria's Secret &amp; Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime. The Company operates as a single segment designed to serve customers worldwide seamlessly through stores and online channels.</p>
<p>In light of the recent options history for Victoria's Secret, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Victoria's Secret</h3>
<ul>
<li>Trading volume stands at 1,216,267, with VSCO's price down by -1.94%, positioned at $26.35.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 5 days.</li>
</ul>
<h3>What The Experts Say On Victoria's Secret</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $36.8.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Telsey Advisory Group persists with their Market Perform rating on Victoria's Secret, maintaining a target price of $40.<br />
&#x2A; An analyst from Goldman Sachs has decided to maintain their Sell rating on Victoria's Secret, which currently sits at a price target of $35.<br />
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Underperform rating on Victoria's Secret with a target price of $35.<br />
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Victoria's Secret with a target price of $34.<br />
&#x2A; An analyst from Telsey Advisory Group persists with their Market Perform rating on Victoria's Secret, maintaining a target price of $40. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Victoria's Secret, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


VSCO

A Closer Look at Victoria's Secret's Options Market Dynamics

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Praxis Precision Medicine</strong>.</p>
<p>Looking at options history for Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) we detected 39 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 23% of the investors opened trades with bullish expectations and 69% with bearish.</p>
<p>From the overall spotted trades, 17 are puts, for a total amount of $1,543,653 and 22, calls, for a total amount of $1,277,845.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $30.0 to $115.0 for Praxis Precision Medicine over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Praxis Precision Medicine's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Praxis Precision Medicine's significant trades, within a strike price range of $30.0 to $115.0, over the past month.</p>
<h3>Praxis Precision Medicine Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740771955_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PRAX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$20.7</td>
<td>$19.2</td>
<td>$20.7</td>
<td>$60.00</td>
<td>$349.8K</td>
<td>5.3K</td>
<td align="right">251</td>
</tr>
<tr>
<td>PRAX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$20.8</td>
<td>$19.2</td>
<td>$20.8</td>
<td>$60.00</td>
<td>$336.9K</td>
<td>5.3K</td>
<td align="right">37</td>
</tr>
<tr>
<td>PRAX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$19.3</td>
<td>$19.2</td>
<td>$19.3</td>
<td>$60.00</td>
<td>$202.6K</td>
<td>5.3K</td>
<td align="right">600</td>
</tr>
<tr>
<td>PRAX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$18.8</td>
<td>$18.1</td>
<td>$18.8</td>
<td>$60.00</td>
<td>$127.8K</td>
<td>5.3K</td>
<td align="right">668</td>
</tr>
<tr>
<td>PRAX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$11.0</td>
<td>$10.6</td>
<td>$11.0</td>
<td>$40.00</td>
<td>$126.5K</td>
<td>1.0K</td>
<td align="right">933</td>
</tr>
</tbody>
</table>
</p>
<h3>About Praxis Precision Medicine</h3>
<p>Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.</p>
<p>Having examined the options trading patterns of Praxis Precision Medicine, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Praxis Precision Medicine</h3>
<ul>
<li>Currently trading with a volume of 2,196,785, the PRAX's price is down by -40.4%, now at $38.76. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 11 days.</li>
</ul>
<h3>What Analysts Are Saying About Praxis Precision Medicine</h3>
<p>2 market experts have recently issued ratings for this stock, with a consensus target price of $130.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $150.<br />
&#x2A; In a cautious move, an analyst from Deutsche Bank downgraded its rating to Buy, setting a price target of $111. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Praxis Precision Medicine with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


PRAX

Market Whales and Their Recent Bets on PRAX Options

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Apollo Global Management</strong>.</p>
<p>Looking at options history for Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) we detected 8 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 75% with bearish.</p>
<p>From the overall spotted trades, 6 are puts, for a total amount of $364,409 and 2, calls, for a total amount of $74,050.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $120.0 to $160.0 for Apollo Global Management over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Apollo Global Management's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Apollo Global Management's substantial trades, within a strike price spectrum from $120.0 to $160.0 over the preceding 30 days.</p>
<h3>Apollo Global Management 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740771950_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>APO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$7.7</td>
<td>$7.3</td>
<td>$7.7</td>
<td>$120.00</td>
<td>$100.8K</td>
<td align="right">3</td>
<td align="right">356</td>
</tr>
<tr>
<td>APO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$1.35</td>
<td>$1.15</td>
<td>$1.2</td>
<td>$125.00</td>
<td>$95.6K</td>
<td align="right">10</td>
<td align="right">904</td>
</tr>
<tr>
<td>APO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$9.7</td>
<td>$9.5</td>
<td>$9.7</td>
<td>$130.00</td>
<td>$80.5K</td>
<td align="right">604</td>
<td align="right">1</td>
</tr>
<tr>
<td>APO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.2</td>
<td>$10.9</td>
<td>$10.9</td>
<td>$160.00</td>
<td>$49.0K</td>
<td align="right">290</td>
<td align="right">15</td>
</tr>
<tr>
<td>APO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$6.4</td>
<td>$6.3</td>
<td>$6.3</td>
<td>$145.00</td>
<td>$30.8K</td>
<td align="right">543</td>
<td align="right">54</td>
</tr>
</tbody>
</table>
</p>
<h3>About Apollo Global Management</h3>
<p>Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Asset Management, Retirement Services, and Principal Investing. It generates maximum revenue from the Retirement Services segment.</p>
<p>After a thorough review of the options trading surrounding Apollo Global Management, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Apollo Global Management</h3>
<ul>
<li>With a volume of 2,935,331, the price of APO is down -0.19% at $147.16. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 62 days.</li>
</ul>
<h3>What Analysts Are Saying About Apollo Global Management</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $183.67.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Apollo Global Management with a target price of $187.<br />
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on Apollo Global Management, which currently sits at a price target of $170.<br />
&#x2A; Consistent in their evaluation, an analyst from Keefe, Bruyette &amp; Woods keeps a Outperform rating on Apollo Global Management with a target price of $194. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Apollo Global Management options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Apollo Global Management's Options Frenzy: What You Need to Know

<p>On surface level, satellite and launch service specialist <strong>Rocket Lab USA Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) presents itself as a sterling opportunity. For one thing, it's positioned as one of the top players in the burgeoning space economy. On another note, the company is coming off the back of a strong first-quarter sales print. Nevertheless, RKLB stock has been hurting in recent sessions and the pain may worsen.</p>
<p>In isolation, RKLB stock should stand out as an unequivocal sector leader. Following the market close on Thursday, Rocket Lab reported <a href="https://www.benzinga.com/general/space/25/02/44027404/rocket-lab-q4-earnings-revenue-beat-eps-beat-new-satellite-product-multi-launch-agreement-shares-slide-on-soft-guidance">fourth-quarter revenue of $132.39 million</a>, beating the <a href="https://www.benzinga.com/calendars/earnings">consensus estimate</a> of $130.58 million. On the bottom line, the space specialist posted a loss of 10 cents per share, <a href="http://pro.benzinga.com/">in line with expectations</a>.</p>
<p>Additionally, Rocket Lab founder and CEO <strong>Peter Beck</strong> introduced Flatellite, a <a href="https://www.benzinga.com/general/space/25/02/44034215/rocket-lab-unveils-flatellite-low-cost-mass-producible-satellite-to-target-large-constellations-amid-weak-q1-guidance">low-cost, mass-producible satellite</a> developed by the company for large constellations. This technology will allow enterprises participating in the space economy to facilitate communication among groups of satellites to perform specialized tasks. Further, the innovation has powerful implications for national security, defense and commercial industries.</p>
<p>So, the question of the hour: why is the market response to the earnings report lackluster? The answer lies in the following guidance.</p>
<p>Rocket Lab anticipates that first-quarter revenue will range from $117 million to $123 million. This guidance conspicuously fell short of analysts' consensus view of $135.67 million. Subsequently, the matter drew unwanted attention toward RKLB's sky-high sales <a href="https://finance.yahoo.com/quote/rklb/key-statistics">multiple</a>, which stands at nearly 27 times trailing-12-month (TTM) revenue.</p>
<p>Unfortunately, the problem is that even assuming sales rise to the highest-analyst <a href="https://finance.yahoo.com/quote/RKLB/analysis/">estimate</a> for fiscal 2025 of $649.78 million, RKLB stock would be trading at a sales multiple of over 15 times. In the first calendar quarter last year, RKLB exchanged hands at only 8.1 times revenue. Hence, the disconnect between Rocket Lab's fourth-quarter performance and market sentiment for its equity.</p>
<h2 class="wp-block-heading">Technical And Statistical Risks Also Cloud RKLB Stock</h2>
<p>While Rocket Lab might seem to be a discounted investment, the problem is professional traders must make a distinction between an entity being undervalued versus merely being cheap. This assessment isn't as easy as it sounds, thereby introducing technical risks to RKLB stock. As if to reinforce the point, RKLB doesn't enjoy a statistically robust framework when responding to extreme volatility.</p>
<p>To be sure, the space economy is a massive industry, one which Morgan Stanley predicts <a href="https://www.benzinga.com/news/earnings/24/10/41227346/the-race-for-space-3-small-cap-space-stocks-to-buy">could reach $1 trillion by 2040</a>. However, McKinley &amp; Company issued a reality check — colloquially a truth bomb — against excessive speculation. "Given the capital-intensive <a href="https://www.mckinsey.com/industries/aerospace-and-defense/our-insights/a-different-space-race-raising-capital-and-accelerating-growth-in-space">nature</a> of space products, [venture capitalists] like to see that companies have the proprietary and unique tech to achieve clear differentiation and a strong ‘competitive moat' to prevent future market share erosion," the consulting firm wrote.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="600" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28142701/RKLB-stock-technical-chart-1024x600.jpg" alt="" class="wp-image-804374" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28142701/RKLB-stock-technical-chart-1024x600.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28142701/RKLB-stock-technical-chart-300x176.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28142701/RKLB-stock-technical-chart-768x450.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28142701/RKLB-stock-technical-chart.jpg 1028w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by TradingView</figcaption></figure></p>
<p>By logical deduction, there are significant technical risks against RKLB stock, especially if it cannot quickly and convincingly storm above the psychological threshold of $20. The longer the security lingers sandwiched between its 50-day and 200-day moving averages (at $26.53 and $13.52, respectively), the more the hot sales multiple may induce anxiety among shareholders — especially shareholders who are already deeply profitable (for now).</p>
<p>To emphasize the risks, RKLB stock by nature is a coin flip. Using data since its public market debut, a position entered at the beginning of the week has a 48.1% chance of rising by the end of it. Over an eight-week period, this baseline probability is 50/50.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28141745/RKLB-stock-probability-gambit-1024x576.jpg" alt="" class="wp-image-804356" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28141745/RKLB-stock-probability-gambit-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28141745/RKLB-stock-probability-gambit-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28141745/RKLB-stock-probability-gambit-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28141745/RKLB-stock-probability-gambit.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure></p>
<p>When calculating probabilities dynamically — in this case, accounting for severe volatility — pricing behaviors shift unfavorably. Following a one-week loss between 10% and 20%, RKLB historically has a 25% chance of rising in the first subsequent week. Over an eight-week holding period, the likelihood of profitability is only 40%.</p>
<p>For this week, RKLB stock is on pace to lose around 17%. Assuming prevailing winds under similar circumstances materialize, the outlook is more negative than positive.</p>
<h2 class="wp-block-heading">Rocket Lab's Wild Nature Delights Agnostic Traders</h2>
<p>Although Rocket Lab may not be the most comfortable investment based on its wild nature, the framework seems to delight agnostic traders who are looking to extract profits no matter the direction.</p>
<p>In this case, while the probabilities may imply a net negative outcome for RKLB stock, the trajectory will likely not be perfectly linear. Running a guided Monte Carlo simulation reflecting RKLB's probability dynamics reveals the possibility of a dead-cat bounce within the next two weeks before ultimately eroding to around where its 200 DMA currently sits.</p>
<p>With this market intelligence, traders can deploy two different options strategies. First, one could consider a 19/20 bull call spread for the options chain expiring March 14. This transaction involves buying the $19 call (at a $182 ask) and simultaneously selling the $20 call (at a $125 bid). The idea is to front run the potential dead-cat bounce.</p>
<p>Traders use the short call sale to offset some of the long call's debit, resulting in a net debit of $57. The maximum reward should RKLB stock reach $20 at expiration is $43, or a 75.4% payout.</p>
<p>However, the most aggressive trade may be the 18/17 bear put spread for the options chain expiring March 28. This expiration period coincides with when RKLB stock is projected to incur the lowest odds of upside success from the anchor point.</p>
<p>Specifically, the above transaction involves buying the $18 put (at a $116 ask) and simultaneously selling the $17 put (at a $73 bid), resulting in a net debit paid of $43. The maximum reward should RKLB stock drop to $17 is $57 or a 132.6% payout.</p>
<p>For the March 28 expiration, speculators can go less aggressive with a 19/18 bear put spread, although the payout diminishes considerably to 72.4% due to the higher likelihood of success.</p>
<p><em>Photo: Shutterstock</em></p>


Earnings

Equities

Short Ideas

RKLB

Options Corner: Traders May Price In A Reality Check For Rocket Lab USA

Small Cap

Press Releases

SSC Security Services Corp. Announces FY2024 Q3 Results With Strongest Q3 Revenue in Company's History

Dividends

SSC Security Services Corp. Announces Thirty Second Dividend Payment

SSC Security Services Corp. Recognized as One of Canada's Top Growing Companies

SSC Security Services Corp. Completes Amalgamation of its Wholly Owned Subsidiaries

SSC Security Services Corp. Announces Thirty Third Dividend Payment

SSC Security Services Corp. Announces FY2024 Year End Results: 18% Adjusted EBITDA per Share growth on 11% Revenue Growth, Buys Back another 3% of the Company

Comments

SSC Security Services

SSC Security Services (SECUF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga